Northstar Neuroscience Receives FDA Approval For A Clinical Study Of Its Cortical Stimulation System For The Treatment Of Major Depressive Disorder

Posted by on October 19th, 2008 at 05:00am

Northstar Neuroscience, Inc. (NASDAQ: NSTR) today announced that the U.S. Food and Drug Administration (FDA) has granted conditional approval of a second clinical study of its Renova™ Cortical Stimulation System for the treatment of major depressive disorder (MDD). With this approval, the Company expects to begin enrolling patients into its PROSPECT II study this quarter, with preliminary results anticipated during the second half of 2009.

Spread the Love & Syndicate
  • del.icio.us
  • YahooMyWeb
  • digg
  • Furl
  • description
  • De.lirio.us
  • co.mments
  • Ma.gnolia
  • Reddit
  • Spurl
  • Psychodynamic Treatment May Help Depression. Results From A Finnish Study
  • CeNeRx BioPharma Initiates Phase II Clinical Trial Of Its Novel Antidepressant Agent Tyrima(TM)
  • Auspex Pharmaceuticals Announces Positive Results From Clinical Study Of SD-254, A Next-Generation Potential Treatment For Depression
  • Novel Antidepressant Valdoxan(R), Receives EMEA CHMP Positive Opinion For Major Depressive Episodes

    • Under Depression

    Leave a Comment for Northstar Neuroscience Receives FDA Approval For A Clinical Study Of Its Cortical Stimulation System For The Treatment Of Major Depressive Disorder

    Required

    Required, hidden

    Trackback this post  |  Subscribe to the comments via RSS Feed

    Recent Blog Posts

    Categories

    Posts by Month

    Resources